These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33100356)

  • 1. Providing Suitable Pediatric Formulations for Canadian Children: A Call for Action.
    Litalien C; Autmizguine J; Carli A; Giroux D; Lebel D; Leclerc JM; Théorêt Y; Gilpin A; Bérubé S
    Can J Hosp Pharm; 2020; 73(4):247-256. PubMed ID: 33100356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups.
    Giacoia GP; Taylor-Zapata P; Mattison D
    Clin Ther; 2008 Nov; 30(11):2097-101. PubMed ID: 19108797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European perspectives on pediatric formulations.
    Breitkreutz J
    Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Prescriptions Requiring Compounding at a Canadian University Affiliated Pediatric Hospital: A Cross-Sectional Study.
    Landry ÉK; Autmizguine J; Bérubé S; Kraus R; Métras MÉ; Lebel D; Litalien C
    Children (Basel); 2023 Jan; 10(1):. PubMed ID: 36670697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Availability of Oral Formulations Labeled for Use in Young Children in Serbia, Germany and the USA.
    Bajcetic M; Kearns GL; Jovanovic I; Brajovic M; van den Anker JN
    Curr Pharm Des; 2015; 21(39):5668-73. PubMed ID: 26323413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Access to age-appropriate essential medicines: a retrospective survey of compounding of medicines for children in hospitals in Nigeria and implications for policy development.
    Orubu ES; Okwelogu C; Opanuga O; Nunn T; Tuleu C
    Health Policy Plan; 2017 Mar; 32(2):225-235. PubMed ID: 28207051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric drug formulations: a review of challenges and progress.
    Ivanovska V; Rademaker CM; van Dijk L; Mantel-Teeuwisse AK
    Pediatrics; 2014 Aug; 134(2):361-72. PubMed ID: 25022739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019.
    delMoral-Sanchez JM; Gonzalez-Alvarez I; Gonzalez-Alvarez M; Navarro-Ruiz A; Bermejo M
    Pharmaceutics; 2020 Apr; 12(4):. PubMed ID: 32244848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric prescribing in tertiary care teaching hospital of Delhi (India): fragmenting medicines for use.
    Tayal H; Roy V; Singhal S; Dubey AP
    Eur J Pediatr; 2020 Sep; 179(9):1435-1443. PubMed ID: 32185474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does EU and US paediatric legislation improve the authorization availability of medicines for children in other countries?
    Volodina A; Shah-Rohlfs R; Jahn A
    Br J Clin Pharmacol; 2023 Mar; 89(3):1056-1066. PubMed ID: 36189466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Devices for securing and administering pediatric compounded oral liquids: survey results from French university hospitals.
    Cavelier M; Hervouët C; Varin R; Gondé H
    Eur J Pediatr; 2024 Jun; 183(6):2805-2810. PubMed ID: 38573361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paediatric oral formulations: Why don't our kids have the medicines they need?
    Juárez-Hernández JE; Carleton BC
    Br J Clin Pharmacol; 2022 Oct; 88(10):4337-4348. PubMed ID: 35803881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the pharmaceutical technologic aspects of oral pediatric drugs on patient-related outcomes: a systematic literature review.
    van Riet-Nales DA; Schobben AF; Egberts TC; Rademaker CM
    Clin Ther; 2010 May; 32(5):924-38. PubMed ID: 20685501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A proposed pediatric biopharmaceutical classification system for medications for chronic diseases in children.
    Bhatt-Mehta V; Hammoud H; Amidon GL
    Eur J Pharm Sci; 2020 Sep; 152():105437. PubMed ID: 32598914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient safety issues associated with the use of compounded medicines as alternatives to approved pharmaceutical products in Europe and how best practice can improve outcomes.
    Isles M
    Int J Risk Saf Med; 2020; 31(3):133-144. PubMed ID: 32538874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of ethanol and other potentially harmful excipients in pediatric oral medicines: survey of community pharmacies in a Nigerian City.
    Soremekun R; Ogbuefi I; Aderemi-Williams R
    BMC Res Notes; 2019 Jul; 12(1):460. PubMed ID: 31349864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
    Giacoia GP; Taylor-Zapata P; Zajicek A
    Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.